A thorough post hoc analysis of the REIN study showed that the nephron-protective effect of angiotensin-converting enzyme (ACE) inhibition in proteinuric CKD patients was maximal in obese CKD patients, but minimal in CKD patients with normal or low BMI [84]. The gene discussed is ACE; the disease is chronic kidney disease.